COVIran Barekat

COVIran Barekat
	A vial of COVIran Barakat
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	BIV1-CovIran; COVIran Barakat; COVIran Barkat; کووایران برکت
Routes of; administration	Intramuscular
ATC code	None;
Legal status
Legal status	Emergency use authorization: IRN; Full and emergency authorizations Full list of COVIran Barekat authorizations

COVIran Barekat^[2] (Persian: کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group.^[3]^[4]^[5] It is an inactivated virus-based vaccine.^[2] Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.^[6]

Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal.^[7] The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2.^[8] Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection.^[9] ^{[further explanation needed]}

As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO.^[10] and the annual production capacity of this vaccine has reached 350 million doses.^[11] Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei^[4] and the President, Ebrahim Raisi.^[12]

A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose.^[13]^[14]

^ Cite error: The named reference :10 was invoked but never defined (see the help page).
^ ^a ^b Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
^ Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.
^ ^a ^b "Iran's leader gets locally made coronavirus vaccine shot". Reuters. 2021-06-25. Retrieved 2021-08-24.
^ "About - شرکت گروه صنایع شفافارمد". 2021-04-15. Retrieved 2021-09-03.
^ Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.
^ Cite error: The named reference Tasnim_2021 was invoked but never defined (see the help page).
^ Setad (EIKO) (2021-06-16). "خلاصه نتایج تست انسانی واکسن کوو ایران برکت" [Summary of the results of COVIran Barekat vaccine's clinical trials] (PDF). Retrieved 2021-09-05.
^ Cite error: The named reference :15 was invoked but never defined (see the help page).
^ "تولید ۶۰ میلیون دُز واکسن برکت در شفافارمد/ آغاز مطالعه بالینی واکسن اختصاصی اُمیکرون | خبرگزاری فارس" [Production of 60 million doses of Barakat vaccine in Shafafarmed / Initiation of clinical study of Omicron specific vaccine]. www.farsnews.ir (in Persian). 2022-02-26. Retrieved 2022-02-27.
^ The production capacity of the Barakat vaccine reached 350 million doses per year Tasnimnews.com, Retrieved 26 April 2022
^ Cite error: The named reference :21 was invoked but never defined (see the help page).
^ "Iranian-made vaccine against Omicron begins clinical trial". Tehran Times. 2022-03-02. Retrieved 2022-03-03.
^ "IRCT | A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age". en.irct.ir. Retrieved 2022-03-03.

[:10-1] Cite error: The named reference :10 was invoked but never defined (see the help page).

[:7-2] Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.

[B-3] Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.

[:5-4] "Iran's leader gets locally made coronavirus vaccine shot". Reuters. 2021-06-25. Retrieved 2021-08-24.

[5] "About - شرکت گروه صنایع شفافارمد". 2021-04-15. Retrieved 2021-09-03.

[6] Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.

[Tasnim_2021-7] Cite error: The named reference Tasnim_2021 was invoked but never defined (see the help page).

[:20-8] Setad (EIKO) (2021-06-16). "خلاصه نتایج تست انسانی واکسن کوو ایران برکت" [Summary of the results of COVIran Barekat vaccine's clinical trials] (PDF). Retrieved 2021-09-05.

[:15-9] Cite error: The named reference :15 was invoked but never defined (see the help page).

[:16-10] "تولید ۶۰ میلیون دُز واکسن برکت در شفافارمد/ آغاز مطالعه بالینی واکسن اختصاصی اُمیکرون | خبرگزاری فارس" [Production of 60 million doses of Barakat vaccine in Shafafarmed / Initiation of clinical study of Omicron specific vaccine]. www.farsnews.ir (in Persian). 2022-02-26. Retrieved 2022-02-27.

[11] The production capacity of the Barakat vaccine reached 350 million doses per year Tasnimnews.com, Retrieved 26 April 2022

[:21-12] Cite error: The named reference :21 was invoked but never defined (see the help page).

[:13-13] "Iranian-made vaccine against Omicron begins clinical trial". Tehran Times. 2022-03-02. Retrieved 2022-03-03.

[:14-14] "IRCT | A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age". en.irct.ir. Retrieved 2022-03-03.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]